BioMedNewsBreaks

WednesdayFeb 17, 2021 10:50 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes on $7.4M Registered Direct Offering, Announces Breakthrough Discoveries

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it had closed on its previously announced registered direct offering. The offering, comprised of 4,222,288 shares of POAI common stock sold at $1.75 per share, totaled $7.4 million in gross proceeds for the company, before expenses were deducted. The shares were priced at-the-market under Nasdaq rules. The announcement also noted that the company issued a concurrent private placement to the same investors; that placement comprised of unregistered warrants up 2,111,144 shares of common stock, priced at $2 per share.…

Continue Reading

WednesdayFeb 17, 2021 10:30 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Executes Purchase Agreement to Raise $10.2M

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has executed a securities purchase agreement. The agreement is intended to raise gross proceeds of $10.2 million through the sale of 1,321,132 shares. The shares will be sold at $7.75 per share through a private investment in public equity (“PIPE”) financing. In the announcement, the company reported that the financing attracted both institutional and accredited investors, with the private placement closing expected on or about Feb. 23, 2021. “We believe these additional resources position…

Continue Reading

TuesdayFeb 16, 2021 2:03 pm

BioMedNewsBreaks – Artelo Biosciences Inc. (NASDAQ: ARTL) Appoints Senior Pharmaceutical Exec as New SVP, Chief Scientific Officer

Artelo Biosciences (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways including the endocannabinoid system, today announced the appointment of Andrew Yates, Ph.D, as senior vice president and chief scientific officer. Dr. Yates is an experienced senior pharmaceutical executive, having most recently served at AstraZeneca in significant roles across a number of functional areas including development and commercial strategy, medical affairs and business development. Notably, Dr. Yates has been extensively involved in the life-cycle management of key multi-billion-dollar products including CRESTOR(R), FORXIGA(R) and KEYTRUDA(R). “We are extremely pleased to announce the…

Continue Reading

TuesdayFeb 16, 2021 11:05 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Completion of European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has made a significant announcement, along with its exclusive German diagnostics development partner, 3a-diagnostics GmbH ("3a"). The companies have completed all actions and procedures required for the European regulatory application for the rapid point-of-care SARS-CoV-2 (COVID-19) RT-PCR Test System. The announcement noted that ISO 13485 approval for 3a as a medical device manufacturer is expected in the next few weeks; 3a also anticipates European regulatory approval as a commercial in vitro diagnostic device (CE-IVD) for COVID-ID Lab by early March. The exclusive lab is designed to be a rapid, accurate and robust test…

Continue Reading

FridayFeb 12, 2021 11:58 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Qualifies to Trade on OTCQX Best Market

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has announced it has qualified to trade on the OTCQX(R) Best Market; the company’s symbol was also upgraded to OTCQX from the OTCQB(R) Venture Market. Effective Friday, Feb. 12, 2021, the company will begin trading using its MGROF symbol. The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. Moving from the OTCQB…

Continue Reading

FridayFeb 12, 2021 11:46 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Announces Change in Management, New Board Appointment

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that Daryl Rebeck will resign from the board and his position as the president of LexaGene effective Feb. 15, 2021. Stephen J. Mastrocola has joined the company’s board of directors and brings almost 40 years of accounting and auditing experience working with public and private companies. “I’m immensely grateful to Daryl for being my partner and helping me found this company four years ago. I would like to thank him for all his hard work and leadership and wish him…

Continue Reading

FridayFeb 12, 2021 10:54 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 Financial Report, Clinical Studies Update

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial numbers for its fiscal 2021 third quarter, ending Dec. 21, 2020. Highlights of the report are the company’s strengthened balance sheet following the closing of its recent underwritten public offering, which resulted in $100 million. In the report, the company also noted that it expects to launch multiple clinical studies during the 2021 calendar year, including crucial Phase 3 clinical studies of PH94B as a…

Continue Reading

ThursdayFeb 11, 2021 2:52 pm

BioMedNewsBreaks – RYAH Group Inc. Enters Strategic Partnership to Establish Market Standard for Vaporizing

RYAH Group, a leading digital health care analytics and technology company, recently entered into a research-and-distribution arrangement with THC Lab. Appearing to be an ideal partner for RYAH as the company expands globally, THC Lab specializes in providing products and services to compounding pharmacies in Italy and other European countries in the specific field of medical cannabis. The agreement outlines the parameters for the launch of RYAH’s IoT dose-measuring Smart-Inhaler and data analytics platform in Italy as well as the Netherlands. “We are confident that together with RYAH we will be able to increase considerably the share of inhaled medical…

Continue Reading

ThursdayFeb 11, 2021 2:33 pm

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Provides Update on Biopesticide Pipeline

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an innovative agriculture biotech company focused on providing natural biological protection for high value crops and other markets. Recently the company provided an update of its biopesticide product pipeline. The company — by extracting natural compounds from within the mustard seed — the mustard plant’s natural defense mechanism — has provided natural solutions to potentially replace widely used harmful synthetics that are being deregistered and banned. A recent article discussing this reads, “As part of the update, the company reported that a U.S. EPA registration already exists for its biopesticide product in…

Continue Reading

ThursdayFeb 11, 2021 10:16 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Ability to Speed Up COVID-19 Testing Using PCR Equipment

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has partnered with a German diagnostics firm to become a leader in commercializing breakthrough tech in rapid, definitive testing for COVID-19 in strategic and convenient point-of-care (“POC”) settings. A recent article noted that, using standard polymerase chain reaction (“PCR”) equipment, XPhyto has the ability to significantly speed up testing for COVID-19. The equipment is commonly found in most analytical laboratories as well as hospitals and a range of POC settings. The announcement was based on the successful trial validation results of XPhyto’s…

Continue Reading